Rep. Jonathan L. Jackson (D-IL) Buys Guardant Health (GH) Stock

Democratic Representative Jonathan L. Jackson bought shares of Guardant Health, Inc. in a trade valued between $15,001 and $50,000 on September 28, 2026. The purchase by the House Democrat was revealed in a periodic transaction report filed with the House of Representatives on October 19, 2026.

GH Guardant Health, Inc.

$157.88 ▲ +55.18% year to date

1M 3M YTD

Daily close · Oct 19, 2026

Inside Representative Jackson's Guardant Health Trade

The transaction details came to light through a mandatory financial disclosure filed under the STOCK Act. According to the disclosure document, Representative Jackson executed the purchase on September 28, 2026, putting money into the precision oncology firm in a trade valued between $15,000 and $50,000. Under congressional disclosure rules, lawmakers report trades using broad dollar ranges rather than exact amounts.

Other Institutional Activity in Guardant Health

Large investment firms have adjusted their holdings in the healthcare company recently. Two Sigma Investments, LP reduced its stake by 510,061 shares, ending with 3,719,301 shares worth about $604,721,135. Capital International Investors trimmed its position by 81,813 shares to hold 3,399,604 shares valued at roughly $552,741,601. Meanwhile, Deep Track Capital, Lp grew its holdings by 55,081 shares, a 1.7% increase, leaving it with 3,393,312 shares worth about $551,718,585 as of June 30, 2026.

Guardant Health, Inc. Stock Holds Steady

Guardant Health shares closed at $177.33 on the day of the trade, September 28, 2026. As of October 20, 2026, the stock recently traded around $157.88. The share price sits below its 50-day moving average of $167.87 and above its 200-day moving average of $127.54.

Recent Earnings

Guardant Health reported trailing twelve-month revenue of $1.18 billion alongside a trailing earnings per share of -$3.50. The company posted a year-over-year revenue growth rate of 44.3% and a net margin of -38.3%. Investors look toward the next earnings report scheduled for November 5, 2026.

Insider Buying and Selling at Guardant Health, Inc.

Company insiders have also transacted in the stock. Co-Chief Executive Officer Amirali Talasaz carried out multiple transactions in June 2026, including acquiring 111,804 shares at a price of $4.18 valued at $467,340.72 on June 26, 2026, and buying 143,028 shares at $4.18 valued at $597,857.04 on June 29, 2026.

Analysts Set New Price Targets

Wall Street analysts maintain a positive view of the company. Piper Sandler maintained an Overweight rating while lifting its price target to $193.00 from $135.00 on August 4, 2026. Stephens & Co. kept an Overweight rating with a target raised to $195.00 from $170.00 on the same day. BTIG reiterated a Buy rating with a $195.00 target on September 2, 2026. Rothschild & Co initiated coverage with a Buy rating and a $203.00 target on September 8, 2026. UBS maintained a Buy rating with a $225.00 target on September 9, 2026. Analysts hold a strong buy consensus on the company with a mean price target of $201.64.

About Guardant Health, Inc.

Guardant Health, Inc. is a precision oncology company based in Palo Alto, California, that develops blood and tissue tests and data sets to help clinicians manage cancer treatment. The company operates in the diagnostics and research sector, employing nearly 2,500 people.

Bottom Line

The disclosure provides a look at lawmaker stock transactions under congressional rules. Observers can monitor further disclosures from members of Congress and watch for the company's upcoming financial results.